Advertisement

Der Nervenarzt

, Volume 83, Issue 12, pp 1582–1589 | Cite as

Repetitive impulsassoziierte Verhaltensstörungen beim Morbus Parkinson

  • R. Katzenschlager
  • K.S. Goerlich
  • T. van Eimeren
Übersichten

Zussamenfassung

Die Parkinson-Erkrankung kann mit einer Reihe repetitiver, impulsassoziierter Verhaltensstörungen einhergehen, die schwerwiegende soziale, berufliche oder finanzielle Folgen nach sich ziehen können. Impulskontrollstörungen (pathologisches Glücksspiel, impulsives Essen oder Kaufen und Hypersexualität) treten bei ca. 13–14% der Parkinson-Patienten auf. Weitere beobachtete Verhaltensstörungen sind das dopaminerge Dysregulationssyndrom (DDS), eine Substanzabhängigkeit mit Verlangen („craving“) nach dopaminergen Substanzen und „punding“ (stundenlange Wiederholung nicht zielorientierter Verhaltensmuster).

Therapiebezogene Risikofaktoren sind Dopaminagonisten für Impulskontrollstörungen und eine hohe dopaminerge Gesamtdosis für DDS und Punding. Gemeinsame Risikofaktoren sind junges Erkrankungsalter, impulsive Persönlichkeit, Depression und möglicherweise Dyskinesien. Auf neuronaler Ebene scheinen diese Verhaltensstörungen mit Veränderungen im Belohnungsnetzwerk und einer Dysfunktion des orbitofrontalen Kortex assoziiert zu sein. Zum Management ist die Evidenzlage bisher unzureichend. Die derzeitige Praxis bei Impulskontrollstörungen besteht in Absetzen bzw. Reduzieren der Dopaminagonisten.

Schlüsselwörter

Morbus Parkinson Repetitive impulsassoziierte Verhaltensstörungen Therapiebezogene Risikofaktoren Dopaminagonisten Belohnungsnetzwerk Orbitofrontaler Kortex 

Repetitive impulse-associated behavioral disorders in Parkinson’s disease

Summary

Parkinson’s disease (PD) is associated with a number of behavioral disorders which may cause considerable social, professional or financial problems. Impulse control disorders (ICDs), such as pathological gambling, binge eating, compulsive shopping and hypersexuality occur in approximately 13–14% of PD patients. Further behavioral disorders are the dopamine dysregulation syndrome (DDS), a substance dependence characterized by craving for dopaminergic substances and punding (prolonged repetitive activities which are not goal-oriented).

Treatment-related risk factors are dopamine agonists for ICDs and a high total dopaminergic dose for DDS and punding. Shared risk factors are young age at onset, impulsive personality traits, depression and possibly dyskinesia. At the neuronal level these behavioral disorders seem to be associated with changes in the reward system and dysfunction of the orbitofrontal cortex. The evidence level for management strategies is at present insufficient. For ICDs current clinical practice consists of discontinuation or reduction of dopamine agonists.

Keywords

Parkinson’s disease Repetitive impulse-associated behavioral disorders Dopamine agonists Reward network Orbitofrontal cortex 

Notes

Interessenkonflikt

Keine Angaben

Literatur

  1. 1.
    Bach JP, Oertel WH, Dodel R et al (2009) Treatment of hypersexuality in Parkinson’s disease with carbamazepine: a case report. Mov Disord 24:1241–1242PubMedCrossRefGoogle Scholar
  2. 2.
    Benincasa D, Pellicano C, Fanciulli A et al (2011) Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson’s disease. Mov Disord 26:355–357PubMedCrossRefGoogle Scholar
  3. 3.
    Bermejo PE (2008) Topiramate in managing impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord 14:448–449PubMedCrossRefGoogle Scholar
  4. 4.
    Cilia R, Ko JH, Cho SS et al (2010) Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiol Dis 39:98–104PubMedCrossRefGoogle Scholar
  5. 5.
    Evans AH, Katzenschlager R, Paviour D et al (2004) Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19:397–405PubMedCrossRefGoogle Scholar
  6. 6.
    Evans AH, Lawrence AD, Cresswell SA et al (2010) Compulsive use of dopaminergic drug therapy in Parkinson’s disease: reward and anti-reward. Mov Disord 25:867–876PubMedCrossRefGoogle Scholar
  7. 7.
    Evans AH, Lawrence AD, Potts J et al (2005) Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 65:1570–1574PubMedCrossRefGoogle Scholar
  8. 8.
    Evans AH, Pavese N, Lawrence AD et al (2006) Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59:852–858PubMedCrossRefGoogle Scholar
  9. 9.
    Fasano A, Ricciardi L, Pettorruso M et al (2011) Management of punding in Parkinson’s disease: an open-label prospective study. J Neurol 258:656–660PubMedCrossRefGoogle Scholar
  10. 10.
    Gerschlager W, Bloem BR (2009) Managing pathological gambling in Parkinson’s disease with enteral levodopa/carbidopa infusions. Mov Disord 24:1858–1860PubMedCrossRefGoogle Scholar
  11. 11.
    Hicks CW, Pandya MM, Itin I et al (2011) Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson’s disease. Parkinsonism Relat Disord 17:379–381PubMedCrossRefGoogle Scholar
  12. 12.
    Katzenschlager R (2008) Störungen von Verhalten und Impulskontrolle beim Morbus Parkinson. Nervenheilkunde 27:721–727Google Scholar
  13. 13.
    Kummer A, Maia DP, Salgado JV et al (2006) Dopamine dysregulation syndrome in Parkinson’s disease: case report. Arq Neuropsiquiatr 64:1019–1022PubMedCrossRefGoogle Scholar
  14. 14.
    Leung KS, Cottler LB (2009) Treatment of pathological gambling. Curr Opin Psychiatry 22:69–74PubMedCrossRefGoogle Scholar
  15. 15.
    Mamikonyan E, Siderowf AD, Duda JE et al (2008) Long-term follow-up of impulse control disorders in Parkinson’s disease. Mov Disord 23:75–80PubMedCrossRefGoogle Scholar
  16. 16.
    Miyasaki JM, Al Hassan K, Lang AE et al (2007) Punding prevalence in Parkinson’s disease. Mov Disord 22:1179–1181PubMedCrossRefGoogle Scholar
  17. 17.
    Moum SJ, Price CC, Limotai N et al (2012) Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS ONE 7:e29768PubMedCrossRefGoogle Scholar
  18. 18.
    Rabinak CA, Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 67:58–63PubMedCrossRefGoogle Scholar
  19. 19.
    Rotondo A, Bosco D, Plastino M et al (2010) Clozapine for medication-related pathological gambling in Parkinson disease. Mov Disord 25:1994–1995PubMedCrossRefGoogle Scholar
  20. 20.
    Silveira-Moriyama L, Evans AH, Katzenschlager R et al (2006) Punding and dyskinesias. Mov Disord 21:2214–2217PubMedCrossRefGoogle Scholar
  21. 21.
    Steeves TD, Miyasaki J, Zurowski M et al (2009) Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 132:1376–1385PubMedCrossRefGoogle Scholar
  22. 22.
    Thomas A, Bonanni L, Gambi F et al (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68:400–404PubMedCrossRefGoogle Scholar
  23. 23.
    Eimeren T van, Ballanger B, Pellecchia G et al (2009) Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson’s disease? Neuropsychopharmacology 34:2758–2766PubMedCrossRefGoogle Scholar
  24. 24.
    Eimeren T van, Pellecchia G, Cilia R et al (2010) Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 75:1711–1716PubMedCrossRefGoogle Scholar
  25. 25.
    Voon V, Hassan K, Zurowski M et al (2006) Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66:1750–1752PubMedCrossRefGoogle Scholar
  26. 26.
    Voon V, Mehta AR, Hallett M (2011) Impulse control disorders in Parkinson’s disease: recent advances. Curr Opin Neurol 24:324–330PubMedCrossRefGoogle Scholar
  27. 27.
    Weintraub D, Koester J, Potenza MN et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589–595PubMedCrossRefGoogle Scholar
  28. 28.
    Weintraub D, Mamikonyan E, Papay K et al (2012) Questionnaire for impulsive-compulsive disorders in Parkinson’s Disease–Rating Scale. Mov Disord 27:242–247PubMedCrossRefGoogle Scholar
  29. 29.
    Weintraub D, Sohr M, Potenza MN et al (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68:963–968PubMedCrossRefGoogle Scholar
  30. 30.
    Witjas T, Baunez C, Henry JM et al (2005) Addiction in Parkinson’s disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 20:1052–1055PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • R. Katzenschlager
    • 1
  • K.S. Goerlich
    • 2
  • T. van Eimeren
    • 2
  1. 1.Neurologische AbteilungDonauspital/SMZ-OstWienÖsterreich
  2. 2.Klinik für NeurologieUniversitätsklinik Schleswig-Holstein, Campus KielKielDeutschland

Personalised recommendations